3:31 PM
Mar 22, 2017
 |  BC Extra  |  Clinical News

Akashi restarting development of DMD candidate

Akashi Therapeutics Inc. (Cambridge, Mass.) said FDA granted the company clearance to resume clinical development of Duchenne muscular dystrophy candidate HT-100. The company said it intends to start a new Phase IIa trial “as quickly as possible.”

In January 2016, Akashi said it suspended dosing and enrollment in all HT-100 trials after a...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >